- Home
- KPTI vs SNAL Comparison
KPTI vs SNAL Comparison
Compare KPTI & SNAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- SNAL
- Stock Information
- Founded
- KPTI 2008
- SNAL 2000
- Country
- KPTI United States
- SNAL United States
- Employees
- KPTI N/A
- SNAL N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- SNAL Computer Software: Prepackaged Software
- Sector
- KPTI Health Care
- SNAL Technology
- Exchange
- KPTI Nasdaq
- SNAL Nasdaq
- Market Cap
- KPTI 66.7M
- SNAL 59.1M
- IPO Year
- KPTI 2013
- SNAL 2022
- Fundamental
- Price
- KPTI $6.94
- SNAL $1.45
- Analyst Decision
- KPTI Strong Buy
- SNAL
- Analyst Count
- KPTI 5
- SNAL 0
- Target Price
- KPTI $61.00
- SNAL N/A
- AVG Volume (30 Days)
- KPTI 142.7K
- SNAL 75.1K
- Earning Date
- KPTI 05-07-2025
- SNAL 03-31-2025
- Dividend Yield
- KPTI N/A
- SNAL N/A
- EPS Growth
- KPTI N/A
- SNAL N/A
- EPS
- KPTI N/A
- SNAL 0.08
- Revenue
- KPTI $145,237,000.00
- SNAL $86,822,973.00
- Revenue This Year
- KPTI $4.37
- SNAL $39.43
- Revenue Next Year
- KPTI $19.07
- SNAL $26.12
- P/E Ratio
- KPTI N/A
- SNAL $19.78
- Revenue Growth
- KPTI N/A
- SNAL 82.23
- 52 Week Low
- KPTI $5.90
- SNAL $0.52
- 52 Week High
- KPTI $24.75
- SNAL $3.42
- Technical
- Relative Strength Index (RSI)
- KPTI 39.17
- SNAL 37.72
- Support Level
- KPTI $5.90
- SNAL $1.33
- Resistance Level
- KPTI $8.45
- SNAL $1.75
- Average True Range (ATR)
- KPTI 1.07
- SNAL 0.23
- MACD
- KPTI -0.01
- SNAL -0.04
- Stochastic Oscillator
- KPTI 23.21
- SNAL 14.12
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About SNAL Snail Inc.
Snail Inc is a global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.